When kidney cancer is not the clear cell type, diagnosing and understanding it becomes more complex, requiring careful evaluation through specialized tests and expert pathology review to determine the best path forward for treatment.

Introduction: When to Seek Diagnostic Testing

Many people discover they have non-clear cell kidney cancer unexpectedly, often during imaging tests done for completely unrelated reasons. More than half of all kidney tumors are found this way, when someone undergoes a scan for back pain, a stomach issue, or another health concern, and the doctor spots something unusual on the kidney. This means that non-renal cell carcinoma of the kidney often doesn’t announce itself with obvious symptoms early on.^[7]

However, there are certain warning signs that should prompt you to see a doctor right away. If you notice blood in your urine, which might make it appear pink, red, or cola-colored, this is an important signal that something needs investigation. A lump or swelling in your side or belly area, persistent pain in your lower back or side that isn’t related to an injury, unexplained weight loss, loss of appetite, ongoing tiredness, or a fever that keeps coming back are all reasons to schedule an appointment with your healthcare provider.^[7]

People who have certain risk factors may benefit from being more vigilant about kidney health. If you smoke, are significantly overweight, have high blood pressure, have been exposed to certain workplace chemicals like trichloroethylene, or have a family history of kidney cancer, you should discuss your risk level with your doctor. Those with genetic conditions affecting the kidneys or chronic kidney disease also need careful monitoring.^[7]

It’s important to understand that kidney and renal pelvis cancer (the area at the center of the kidney that collects urine) is a disease where cells grow out of control. The kidneys are bean-shaped organs located behind your liver and stomach, one on each side of your body. They filter your blood to remove waste products and make urine. When cancer develops in these organs, it can affect how well they perform this vital job.^[7]

Understanding Non-Clear Cell Renal Cell Carcinoma

Not all kidney cancers are the same. The most common type, called renal cell carcinoma, accounts for about 85% of all kidney cancers. Within this group, clear cell renal cell carcinoma is by far the most frequent, making up roughly 75 to 80% of cases. The remaining cases are what doctors call non-clear cell renal cell carcinomas, which together represent about 20 to 25% of all kidney cancers.^[2][4]

Non-clear cell kidney cancer is actually an umbrella term that covers many different subtypes, each with unique characteristics. The main types include papillary renal cell carcinoma (which itself has two subtypes, type 1 and type 2), chromophobe renal cell carcinoma, collecting duct carcinoma, and renal medullary carcinoma. There are also rarer forms like clear cell papillary, translocation-associated renal cell carcinoma, and tumors linked to specific genetic changes.^[2][5]

Papillary renal cell carcinoma accounts for about 10 to 15% of kidney cancers. Under the microscope, these cancers form little finger-like projections called papillae. Chromophobe renal cell carcinoma makes up roughly 5% of cases, with cells that appear larger and have prominent borders. Some types are extremely rare, such as collecting duct carcinoma and medullary carcinoma, each representing only about 1% of cases. Collecting duct cancer is aggressive and arises from the collecting system of the kidney, while medullary cancer often occurs in young African Americans with sickle cell trait and is also very aggressive.^[4][5]

About 5% of renal cell cancers have what are called sarcomatoid features, meaning that some cancer cells look like sarcoma cells when examined under a microscope. This type tends to grow more quickly than other kidney cancers and is often discovered at a more advanced stage. Despite these differences in appearance, the symptoms and treatment approaches for sarcomatoid kidney cancer are similar to other types of renal cell cancer.^[5]

Classic Diagnostic Methods

When doctors suspect kidney cancer, they use a combination of tests to confirm the diagnosis and understand exactly what type of cancer is present. The diagnostic process usually starts with simpler tests and moves to more detailed imaging and laboratory work as needed. Because non-clear cell kidney cancers behave differently from clear cell types, accurate identification of the specific subtype is crucial for planning the best treatment approach.^[2]

Imaging Tests

Imaging studies are the backbone of kidney cancer diagnosis. A computed tomography scan, commonly called a CT scan, is one of the most important tools doctors use. This test creates detailed, three-dimensional pictures of your kidney and surrounding tissues using X-rays taken from multiple angles. A CT scan can show the size and location of a tumor, whether it has spread into nearby blood vessels or lymph nodes, and sometimes can give clues about whether a mass is cancerous or benign. You might receive contrast dye through a vein before the scan to make the images clearer.^[7]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. MRI can be especially helpful when doctors need to see the relationship between a tumor and blood vessels, or when a person cannot receive contrast dye used in CT scans. Like a CT scan, an MRI is painless and takes place while you lie still on a table that slides into a tube-shaped machine.^[7]

Ultrasound is another imaging method that uses sound waves to create pictures of the inside of your body. A renal ultrasound can help determine whether a lump on the kidney is a fluid-filled cyst (usually not cancer) or a solid mass (more likely to be cancer). It’s completely painless and doesn’t use radiation. In some cases, doctors perform a specialized ultrasound called a transrectal ultrasound during a biopsy of the kidney.^[7]

Chest X-rays or CT scans of the chest may be done to check whether cancer has spread to the lungs, which is one of the more common places kidney cancer can travel. Bone scans might be ordered if there’s concern that cancer has reached the bones. These tests use a small amount of radioactive material that collects in areas where bone is actively changing, which can indicate the presence of cancer.^[7]

Urine and Blood Tests

Urinalysis, or urine testing, is a simple but important diagnostic step. The presence of blood in the urine, even if you can’t see it with your naked eye, can be detected through this test and may indicate kidney cancer. However, blood in the urine can also be caused by many other conditions, such as infections, kidney stones, or other urinary tract problems, so it’s not definitive on its own.^[7]

Blood tests help doctors understand how well your kidneys are functioning and check your overall health. These tests might look at creatinine levels (a waste product that healthy kidneys filter out), blood counts to check for anemia, and other markers of organ function. Some blood tests can detect substances released by cancer cells, though there is no specific blood test that definitively diagnoses kidney cancer.^[7]

Biopsy and Pathology

While imaging tests can strongly suggest kidney cancer, the only way to know for certain what type of cancer is present is through a biopsy. During a biopsy, a doctor removes a small sample of tissue from the suspicious area, usually using a thin needle guided by ultrasound or CT imaging. You’ll receive local anesthesia to numb the area, and sometimes light sedation to help you relax. The tissue sample is then sent to a laboratory where a specialist doctor called a pathologist examines it under a microscope.^[2]

The pathologist’s role is critical in diagnosing non-clear cell kidney cancer. They look at the characteristics of the cells, how they’re arranged, and other features to determine the exact subtype of cancer. This is particularly important because non-clear cell types can look quite different from one another. For example, papillary cancer has its distinctive finger-like projections, while chromophobe cancer has larger cells with specific features. Some subtypes, like translocation-associated cancers, require special genetic testing to identify.^[2][5]

Grading the Cancer

Once the type of kidney cancer is identified, the pathologist also assigns a grade to the cancer. Grading tells doctors how much the cancer cells look like normal, healthy kidney cells. For clear cell and papillary renal cell cancers, grades range from 1 to 4. Grade 1 means the cancer cells look more like normal cells and tend to grow slowly, while grade 4 means they look very abnormal and are likely to grow and spread more quickly. Currently, there is no standardized grading system for chromophobe renal cell cancer.^[5]

The grade helps predict how the cancer might behave. Lower-grade cancers are generally less aggressive and less likely to spread to other parts of the body, while higher-grade cancers tend to be more aggressive and have a higher risk of spreading. This information, combined with the stage of the cancer (how far it has spread), helps your medical team recommend the most appropriate treatment approach.^[5]

Genetic and Molecular Testing

Advances in medical science have made it increasingly important to understand the genetic and molecular characteristics of non-clear cell kidney cancers. Next-generation sequencing and other molecular tests can identify specific genetic changes in cancer cells. For instance, some papillary kidney cancers have changes in a gene called MET, while others have different genetic alterations. Understanding these molecular details can help doctors choose targeted therapies that specifically attack cancer cells based on their genetic makeup.^[2][6]

Germline testing, which looks at the genes you were born with rather than just the genes in the cancer cells, is also becoming more important. Some people inherit genetic changes that increase their risk of developing kidney cancer. Knowing about these hereditary factors not only helps guide treatment but also helps family members understand their own cancer risk. If you have multiple family members with kidney cancer, early-onset disease, or certain other features, your doctor might recommend genetic counseling and testing.^[2][6]

Diagnostic Tests for Clinical Trial Qualification

If you or your doctor are considering enrollment in a clinical trial, you’ll likely need to undergo additional testing beyond the standard diagnostic workup. Clinical trials are research studies that test new treatments or new ways of using existing treatments. They represent an important option for people with non-clear cell kidney cancer because these subtypes are less common and often don’t respond as well to standard therapies developed primarily for clear cell disease.^[2][6]

Each clinical trial has specific entry requirements called eligibility criteria. These criteria ensure that the study enrolls patients who are most likely to benefit from the experimental treatment and who can safely participate. The testing required to determine if you’re eligible varies depending on the trial, but there are some common elements across many studies for non-clear cell kidney cancer.^[2]

Histology Confirmation

Most clinical trials for non-clear cell kidney cancer require pathology confirmation of the specific subtype you have. This means your tumor tissue must be examined by a pathologist who confirms, for example, that you have papillary type 1, chromophobe, or another specific non-clear cell subtype. Some trials focus on a single subtype, while others may include multiple non-clear cell types but analyze results separately for each group. The trial may require that your tissue be reviewed by their own pathology team to ensure accurate classification.^[2][6]

Molecular and Genetic Profiling

Many modern clinical trials, especially those testing targeted therapies, require detailed molecular profiling of your tumor. This might involve next-generation sequencing to identify specific gene mutations or alterations. For example, a trial testing a drug that targets MET-driven cancers would require proof that your tumor has MET gene alterations. Similarly, trials for tumors with fumarate hydratase gene inactivation or other specific molecular features would need testing to confirm these characteristics are present.^[2][6]

These molecular tests are typically performed on tissue from your original biopsy or surgery. If that tissue is not available or suitable for testing, you might need a new biopsy specifically to obtain fresh tissue for analysis. The testing process can take several weeks, so it’s important to start this early if you’re considering a clinical trial.^[2]

Imaging and Staging Requirements

Clinical trials usually require recent imaging studies to document the extent of your disease and establish a baseline for measuring how well the treatment works. You’ll typically need CT scans of your chest, abdomen, and pelvis within a specific timeframe before starting the trial, often within 4 to 6 weeks. Some trials also require MRI of the brain to check for any cancer spread that might not be causing symptoms yet.^[2]

The imaging results help determine your disease stage, which describes how far the cancer has spread. Many trials are designed for patients with advanced or metastatic disease (cancer that has spread beyond the kidney), so you would need imaging evidence of this. Other trials might focus on earlier-stage disease, requiring that the cancer is still confined to the kidney or nearby areas.^[2]

Performance Status and Organ Function Tests

Your overall health and how well you’re able to function in daily life is measured using something called a performance status score. This is usually assessed with standardized scales that rate your activity level from fully active to completely bedridden. Most clinical trials require that participants have a good performance status, meaning you’re able to care for yourself and are up and about at least half of your waking hours.^[2]

Blood tests to check how well your organs are functioning are standard requirements for clinical trial entry. These include tests of kidney function, liver function, blood cell counts, and sometimes heart function tests like an electrocardiogram (EKG) or echocardiogram. The trial protocol specifies acceptable ranges for these values. For kidney cancer patients, this is particularly important because many people have only one kidney or reduced kidney function after surgery, and some treatments can stress the remaining kidney.^[2]

Previous Treatment History

Clinical trials often have specific requirements about previous treatments. Some trials are designed for people who have never received treatment for their cancer (called “treatment-naive” or “first-line” trials). Others are specifically for patients whose cancer has grown despite previous treatments (called “second-line” or “later-line” trials). You’ll need documentation of any prior surgeries, radiation, or systemic therapies you’ve received, including when you received them and how your cancer responded.^[2][6]